The Claim
In patients with homozygous familial hypercholesterolemia (HoFH) who are already receiving standard lipid-lowering therapy with statins and ezetimibe, the addition of a PCSK9 inhibitor is associated with a mean low-density lipoprotein cholesterol (LDL-C) reduction of -8.6% (standard deviation 12.1%), and 70.8% of these patients do not achieve the recommended 15% reduction threshold for continuing treatment.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with a rare cholesterol condition called HoFH who are already on cholesterol meds, adding a newer drug (PCSK9 inhibitor) barely lowers bad cholesterol for most — and 7 out of 10 don’t get enough benefit to keep taking it.
See the scientific wording
In patients with homozygous familial hypercholesterolemia (HoFH) receiving standard lipid-lowering therapy including statins and ezetimibe, adding a PCSK9 inhibitor is associated with a mean LDL-C reduction of only -8.6% (SD 12.1%), with 70.8% of patients failing to achieve the 15% reduction threshold recommended for treatment continuation.
What the research says
1 studyThe study looked at adding PCSK9 inhibitors to usual cholesterol drugs in people with a rare genetic condition, and found it barely lowered bad cholesterol for most people—just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.